Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

New use of 3-methyl-1-phenyl-2-pyrazoline-5-ketone

A technology of pyrazoline and phenyl, which is applied in the field of new application of 3-methyl-1-phenyl-2-pyrazolin-5-one, which can solve the problem that is difficult to cure, cannot prevent recurrence, and affects the quality of life of patients And other issues

Active Publication Date: 2012-08-29
NANJING SIMCERE DONGYUAN PHARM CO LTD +1
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The clinical treatment of this disease is aimed at temporary relief, it is difficult to cure it, and it cannot stop the recurrence, which seriously affects the quality of life of the patient.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • New use of 3-methyl-1-phenyl-2-pyrazoline-5-ketone
  • New use of 3-methyl-1-phenyl-2-pyrazoline-5-ketone

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0016] Embodiment 1 medicine preparation

[0017] Get propranolol hydrochloride 5g and take 50% ethanol as solvent, make medicine dissolve, add Azone-propylene glycol 5ml as composite accelerator, add PVPK305g to be film-forming material, add 50% ethanol to 100ml, prepare propranolol hydrochloride milk liniment.

[0018] The Edaravone injection used in the following examples is a commercially available drug; trade name: Bicun; specification: 10mg / 5mL; production unit: Nanjing Xiansheng Dongyuan Pharmaceutical Co., Ltd.

[0019] The methotrexate for injection used in the following examples is a commercially available drug; specification: 0.1 g / bottle; production unit: Jiangsu Hengrui Medicine Co., Ltd.

Embodiment 2

[0020] Example 2 Edaravone Animal Model Evaluation of Therapeutic Effect on Psoriasis

[0021] Forty-four guinea pigs with a body weight of 300-400 g, half male and half male, were randomly divided into a blank group of 10 and a model group of 34 guinea pigs. Each animal in the model group was coated with 5% propranolol hydrochloride emulsion liniment on the left auricle skin (0.3g / cm2) with a glass rod, twice a day for 2 consecutive weeks. After the last administration, 4 guinea pigs in the normal group and 4 guinea pigs in the model group were killed to take skin samples of the left auricle, fixed in formaldehyde, stained with HE, and observed with a light microscope to evaluate the quality of the model.

[0022] The remaining 30 guinea pigs in the model group were randomly divided into 5 groups, namely the model group, the positive drug control group of methotrexate (1 mg / kg), and the high, medium and low dose (6, 3, 1.5 mg / kg) groups of edaravone. The model group did not ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides application of 3-methyl-1-phenyl-2-pyrazoline-5-ketone, pharmaceutically acceptable salts thereof, or a medicine composition containing any one of the 3-methyl-1-phenyl-2-pyrazoline-5-ketone, and pharmaceutically acceptable salts thereof in preparing medicine for preventing and / or treating psoriasis.

Description

technical field [0001] The invention provides the application of 3-methyl-1-phenyl-2-pyrazolin-5-one in the preparation of medicines for preventing and / or treating psoriasis. Background technique [0002] Psoriasis (psoriasis) is a relatively common chronic inflammatory skin disease with genetic predisposition. It is currently considered to be an immune inflammatory disease controlled by polygenes and closely related to environmental factors. The clinical symptoms are mainly characterized by silvery white scales covering the rash, film phenomenon and spotting bleeding after peeling off, and some patients are accompanied by joint lesions. Its histopathology mainly manifests as hyperplasia of keratinocytes, accumulation of inflammatory cells, proliferation and expansion of blood vessels in the dermal papilla, etc., and the expression of various cytokines in the skin lesions increases, and about 1 / 3 of the affected patients are accompanied by progressive arthritis . The clini...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/4152A61P17/06
Inventor 杨士豹华垚
Owner NANJING SIMCERE DONGYUAN PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com